Reach Separations celebrates 5th birthday with record year
The company’s growth has been driven by export, with a three-fold increase in activity outside of the UK during 2016,
Reach Separations, a UK-based purification specialist, has marked its fifth anniversary with a record year of growth following a surge in demand for its small molecule synthesis capabilities from pharmaceutical companies across Europe.
Reach Separations, which is headquartered at BioCity in Nottingham, has grown by one third since 2015 and is now working with most of the world’s big pharma firms along with many contract research organisations (CROs) that are involved in developing new compounds.
The company’s growth has been driven by export, with a three-fold increase in activity outside of the UK during 2016, and follows significant investment in analytical equipment and purification systems. This has enabled it to increase chromatography capacity to support clients working in drug discovery that require purified materials under tight timescales.
Reach Separations has carved a niche for itself in the purification services space by supporting research chemists and scientists. Over the past 5 years, its team has established itself as one of the most sophisticated and reliable chromatography purification providers in the global contract services market.
The company’s technical group is headed by director and former Separation Science Group Leader at AstraZeneca, Phil Abbott, who has worked in the pharmaceutical industry for around 25 years.
He said: “We are delighted with the progress the company has made since we started. I believe our growth has been fuelled by our reputation to simply deliver a high quality purification and analysis service in a dependable and speedy manner.
“Once we get the opportunity to work with a new chemistry group, they then tend to use us again and again as they know they can rely on our team for a rapid turnaround time on materials they send to our lab for either testing or purification.
“As our capacity and capabilities have extended, it’s opened up new opportunities in new markets, which has led to over 60% of our business now coming from clients outside of the UK.”
To support business growth, Reach Separations has grown to 10 people and is currently recruiting for several new positions to support its expansion plans in 2017.
Phil continued: “We will certainly be on the lookout for talented scientists over the next year that we will train to become highly skilled chromatographers. That’s our commitment to our team.
“We also have plans to make further investment in technology and equipment that will raise the bar even further,” added Phil.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance